ObsEva (OBSV) Competitors

OBSV vs. SKYE, SNTI, DARE, CELU, and BCTX

Should you be buying ObsEva stock or one of its competitors? The main competitors of ObsEva include Skye Bioscience (SKYE), Senti Biosciences (SNTI), Dare Bioscience (DARE), Celularity (CELU), and Briacell Therap (BCTX). These companies are all part of the "pharmaceutical products" industry.

How does ObsEva compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

: Skye Bioscience's return on equity of -143.59% beat ObsEva's return on equity.
Company Net Margins Return on Equity Return on Assets
Skye Bioscience N/A -143.59% -119.89%
ObsEva N/A -416.36% -92.01%
: Skye Bioscience is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Skye Bioscience N/A N/A -$55.92M -$1.40 N/A
ObsEva N/A N/A -$58.38M -$0.92 N/A
: Skye Bioscience has a beta of 3.03, suggesting that its share price is 203% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.
: In the previous week, Skye Bioscience had 1 more articles in the media than ObsEva. MarketBeat recorded 1 mentions for Skye Bioscience and 0 mentions for ObsEva. Skye Bioscience's average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.
Company Overall Sentiment
Skye Bioscience Neutral
ObsEva Neutral
: Skye Bioscience currently has a consensus price target of $9.80, suggesting a potential upside of 1,017.19%. Given Skye Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Skye Bioscience is more favorable than ObsEva.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Skye Bioscience
1 Sell rating(s)
2 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
2.63
ObsEva
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 3.0% of Skye Bioscience shares are held by insiders. Comparatively, 14.4% of ObsEva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-143.59%	-119.89%
ObsEva	N/A	-416.36%	-92.01%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.40	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Company	Overall Sentiment
Skye Bioscience	Neutral
ObsEva	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Skye Bioscience beats ObsEva on 9 of the 13 factors compared between the two stocks.

How does ObsEva compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

: Senti Biosciences' return on equity of -301.48% beat ObsEva's return on equity.
Company Net Margins Return on Equity Return on Assets
Senti Biosciences N/A -301.48% -90.03%
ObsEva N/A -416.36% -92.01%
: ObsEva has lower revenue, but higher earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Senti Biosciences $20K 1,485.38 -$61.44M -$3.19 N/A
ObsEva N/A N/A -$58.38M -$0.92 N/A
: Senti Biosciences has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.
: In the previous week, Senti Biosciences had 1 more articles in the media than ObsEva. MarketBeat recorded 1 mentions for Senti Biosciences and 0 mentions for ObsEva. Senti Biosciences' average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.
Company Overall Sentiment
Senti Biosciences Neutral
ObsEva Neutral
: Senti Biosciences presently has a consensus price target of $8.50, suggesting a potential upside of 790.99%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Senti Biosciences is more favorable than ObsEva.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Senti Biosciences
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.80
ObsEva
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-301.48%	-90.03%
ObsEva	N/A	-416.36%	-92.01%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	1,485.38	-$61.44M	-$3.19	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Company	Overall Sentiment
Senti Biosciences	Neutral
ObsEva	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Senti Biosciences beats ObsEva on 10 of the 14 factors compared between the two stocks.

How does ObsEva compare to Dare Bioscience?

ObsEva (NASDAQ:OBSV) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

: 17.5% of ObsEva shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 4.8% of Dare Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: In the previous week, ObsEva's average media sentiment score of 0.00 equaled Dare Bioscience'saverage media sentiment score.
Company Overall Sentiment
ObsEva Neutral
Dare Bioscience Neutral
: ObsEva has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.
: Dare Bioscience has higher revenue and earnings than ObsEva. Dare Bioscience is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ObsEva N/A N/A -$58.38M -$0.92 N/A
Dare Bioscience $1.03M 46.22 -$13.40M -$1.25 N/A
: Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 205.81%. Given Dare Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Dare Bioscience is more favorable than ObsEva.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ObsEva
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Dare Bioscience
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: Dare Bioscience's return on equity of 0.00% beat ObsEva's return on equity.
Company Net Margins Return on Equity Return on Assets
ObsEva N/A -416.36% -92.01%
Dare Bioscience N/A N/A -56.52%

Company	Overall Sentiment
ObsEva	Neutral
Dare Bioscience	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
Dare Bioscience	$1.03M	46.22	-$13.40M	-$1.25	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Dare Bioscience	N/A	N/A	-56.52%

Summary

Dare Bioscience beats ObsEva on 8 of the 12 factors compared between the two stocks.

How does ObsEva compare to Celularity?

Celularity (NASDAQ:CELU) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

: In the previous week, Celularity had 2 more articles in the media than ObsEva. MarketBeat recorded 2 mentions for Celularity and 0 mentions for ObsEva. Celularity's average media sentiment score of 0.20 beat ObsEva's score of 0.00 indicating that Celularity is being referred to more favorably in the media.
Company Overall Sentiment
Celularity Neutral
ObsEva Neutral
: Celularity has higher revenue and earnings than ObsEva. Celularity is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Celularity $54.22M 0.51 -$57.89M -$3.33 N/A
ObsEva N/A N/A -$58.38M -$0.92 N/A
: Celularity has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.
: 19.0% of Celularity shares are owned by institutional investors. Comparatively, 17.5% of ObsEva shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 14.4% of ObsEva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: ObsEva has a net margin of 0.00% compared to Celularity's net margin of -198.75%. Celularity's return on equity of 0.00% beat ObsEva's return on equity.
Company Net Margins Return on Equity Return on Assets
Celularity -198.75% N/A -65.03%
ObsEva N/A -416.36% -92.01%
: Celularity currently has a consensus price target of $6.00, indicating a potential upside of 529.66%. Given Celularity's stronger consensus rating and higher probable upside, analysts clearly believe Celularity is more favorable than ObsEva.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celularity
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
ObsEva
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Overall Sentiment
Celularity	Neutral
ObsEva	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$54.22M	0.51	-$57.89M	-$3.33	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-198.75%	N/A	-65.03%
ObsEva	N/A	-416.36%	-92.01%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Celularity beats ObsEva on 11 of the 15 factors compared between the two stocks.

How does ObsEva compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

: In the previous week, Briacell Therap's average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.
Company Overall Sentiment
Briacell Therap Neutral
ObsEva Neutral
: Briacell Therap is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Briacell Therap N/A N/A -$26.31M -$23.33 N/A
ObsEva N/A N/A -$58.38M -$0.92 N/A
: Briacell Therap has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.
: 15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 0.7% of Briacell Therap shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Briacell Therap's return on equity of -173.08% beat ObsEva's return on equity.
Company Net Margins Return on Equity Return on Assets
Briacell Therap N/A -173.08% -139.64%
ObsEva N/A -416.36% -92.01%
: Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than Briacell Therap.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Briacell Therap
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
ObsEva
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Overall Sentiment
Briacell Therap	Neutral
ObsEva	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-173.08%	-139.64%
ObsEva	N/A	-416.36%	-92.01%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

ObsEva beats Briacell Therap on 6 of the 10 factors compared between the two stocks.

Get ObsEva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBSV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBSV vs. The Competition

Export

Metric	ObsEva	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.94M	$892.88M	$6.25B	$11.87B
Dividend Yield	N/A	4.84%	2.73%	5.21%
P/E Ratio	0.00	1.72	29.04	28.47
Price / Sales	N/A	120.50	476.61	60.94
Price / Cash	N/A	20.07	27.62	36.52
Price / Book	N/A	7.60	9.67	6.67
Net Income	-$58.38M	-$4.80M	$3.55B	$332.53M

ObsEva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
SKYE Skye Bioscience	1.7629 of 5 stars	$0.89 -3.9%	$9.80 +996.1%	N/A	$31.41M	N/A	N/A	11	Gap Up
SNTI Senti Biosciences	2.5988 of 5 stars	$0.98 +3.0%	$8.50 +764.0%	N/A	$30.64M	$20K	N/A	4
DARE Dare Bioscience	2.0579 of 5 stars	$2.10 -4.1%	$10.00 +376.2%	N/A	$30.58M	$1.03M	N/A	30	Upcoming Earnings Gap Up
CELU Celularity	1.6052 of 5 stars	$0.96 -7.7%	$6.00 +525.0%	N/A	$29.99M	$40.58M	N/A	220	Earnings Report Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OBSV) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ObsEva (OBSV) Competitors

OBSV vs. SKYE, SNTI, DARE, CELU, and BCTX

How does ObsEva compare to Skye Bioscience?

Summary

How does ObsEva compare to Senti Biosciences?

Summary

How does ObsEva compare to Dare Bioscience?

Summary

How does ObsEva compare to Celularity?

Summary

How does ObsEva compare to Briacell Therap?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBSV vs. The Competition

ObsEva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ObsEva (OBSV) Competitors

OBSV vs. SKYE, SNTI, DARE, CELU, and BCTX

How does ObsEva compare to Skye Bioscience?

Summary

How does ObsEva compare to Senti Biosciences?

Summary

How does ObsEva compare to Dare Bioscience?

Summary

How does ObsEva compare to Celularity?

Summary

How does ObsEva compare to Briacell Therap?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBSV vs. The Competition

ObsEva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools